A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

Recruiting now · Phase 2

Conditions studied: Endometrial Adenocarcinoma

In brief

This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.

Key facts

Study ID

NCT05548296

Run by

Acrivon Therapeutics

People needed

350

Starts

2022-08-29

Expected to finish

2027-11-30

Last updated by the study team

2026-06-15

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey, United States (enrolling)
• HonorHealth — Phoenix, Arizona, United States (enrolling)
• Dana Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
• HCA Midwest — Kansas City, Missouri, United States (enrolling)
• City of Hope National Medical Center — Duarte, California, United States (enrolling)
• UC San Diego Moores Cancer Center — La Jolla, California, United States (enrolling)
• Trials365, LLC — Shreveport, Louisiana, United States (enrolling)
• Cedars Sinai Medical Center — Los Angeles, California, United States (enrolling)
• Karmanos Cancer Institute — Detroit, Michigan, United States (enrolling)
• University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States (enrolling)
• Stanford Cancer Center — Palo Alto, California, United States (enrolling)
• University of California, Davis Comprehensive Cancer Center — Sacramento, California, United States (enrolling)
• University of California Los Angeles (UCLA) — Santa Monica, California, United States (enrolling)
• University of Colorado — Aurora, Colorado, United States (enrolling)
• University of Iowa — Iowa City, Iowa, United States (enrolling)
• LSU Health Sciences — New Orleans, Louisiana, United States (enrolling)
• Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida, United States (enrolling)
• Emory University — Atlanta, Georgia, United States (enrolling)
• Hoag Cancer Center — Newport Beach, California, United States (enrolling)
• Northwestern Medicine — Chicago, Illinois, United States (enrolling)
• University of Illinois Cancer Center — Chicago, Illinois, United States (enrolling)
• University of Chicago Medicine — Chicago, Illinois, United States (enrolling)
• Carle Cancer Center — Urbana, Illinois, United States (enrolling)
• Ascension St. Vicent Hospital, Inc. — Indianapolis, Indiana, United States (enrolling)
• Rutgers Cancer Institute of NJ — New Brunswick, New Jersey, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.